Rationale for Combining PARP Inhibitors With Other Therapies in Prostate Cancer

In this episode, Karim Fizazi, MD, PhD, and Joaquin Mateo, MD, PhD, discuss the underlying rationale for using PARP inhibitors in combination with other therapies to treat men with prostate cancer including:

• Possible synergy between PARP inhibitors and androgen receptor–directed therapy
• Rationale for PARP inhibitors and immunotherapy combinations
• Benefits and challenges of combining DNA damaging agents and PARP inhibitor

Presenters:

Karim Fizazi, MD, PhD
Full Professor
Cancer Medicine
Institut Gustave Roussey
Villejuif, France

Joaquin Mateo, MD, PhD
Attending Physician
Medical Oncology
Vall d’Hebron University Hospital,
Barcelona, Spain

Content is part of an online program supported by an educational grant from Pfizer Inc.

Link to full program, including associated downloadable Podcast Pearls slidesets, expert analysis, and expert commentary:
https://bit.ly/3spLzqa

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.